A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

Name: A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)
Published: 2022
License: Public Domain

Sun Yat-sen University · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

unresectable hepatocellular carcinoma, hepatocellular carcinoma by bclc stage, hepatic arterial infusion chemotherapy, bevacizumab, sintilimab, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

Related documents